Our goal is to detect cancer relapse early using cell-free DNA.

Circulating tumor DNA (ctDNA) is a component of cell-free DNA that is shed by malignant tumors. Levels of ctDNA are typically low, especially in non-metastatic cancer patients, requiring highly precise methods for detection and quantitation. 

Such methods have the potential to revolutionize cancer care through noninvasive tumor monitoring, earlier cancer detection, therapeutic response prediction, and treatment personalization based on real-time oncogenomic signatures.

We are further developing these technologies in our lab, and applying them to translational research questions as demonstrated in our Cancer Discovery publication: